Increased Incidence of Post-transplant Lymphoproliferative Disorder in Autoimmune Liver Disease: An Irish National Experience

Gao, 2003, Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University, J Heart Lung Transplant, 22, 505, 10.1016/S1053-2498(02)01229-9 Watt, 2009, Long-term probability of and mortality from de novo malignancy after liver transplantation, Gastroenterology, 137, 2010, 10.1053/j.gastro.2009.08.070 Schrem, 2013, Incidence and long-term risk of de novo malignancies after liver transplantation with implications for prevention and detection, Liver Transpl, 19, 1252, 10.1002/lt.23722 Mukthinuthalapati, 2016, Incidence, risk factors and outcomes of de novo malignancies post liver transplantation, World J Hepatol, 8, 533, 10.4254/wjh.v8.i12.533 Swerdlow, 2008 Evens, 2010, Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era, J Clin Oncol, 28, 1038, 10.1200/JCO.2009.25.4961 Trappe, 2010, Sequential treatment with Rituximab and CHOP chemotherapy in B-cell PTLD; moving forward to a first standard of care: results from a prospective international multicenter trial, Blood Cockfield, 2001, Identifying the patient at risk for post-transplant lymphoproliferative disorder, Transpl Infect Dis, 3, 70, 10.1034/j.1399-3062.2001.003002070.x Tsai, 2001, Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients, Transplantation, 71, 1076, 10.1097/00007890-200104270-00012 Tsai, 2008, Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids, Am J Transplant, 8, 984, 10.1111/j.1600-6143.2008.02167.x Caillard, 2005, Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression, Transplantation, 80, 1233, 10.1097/01.tp.0000179639.98338.39 Evens, 2010, Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy, Curr Oncol Rep, 12, 383, 10.1007/s11912-010-0132-1 Koyabu, 2010, Analysis of regulatory T cells and IgG4-positive plasma cells among patients of IgG4-related sclerosing cholangitis and autoimmune liver diseases, J Gastroenterol, 45, 732, 10.1007/s00535-010-0199-3 Sakaki, 2008, Intrahepatic status of regulatory T cells in autoimmune liver diseases and chronic viral hepatitis, Hepatol Res, 38, 354, 10.1111/j.1872-034X.2007.00284.x Martins, 1996, Elevation of gamma delta T lymphocytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other autoimmune liver diseases, Hepatology, 23, 988 Kita, 2001, The lymphoid liver: considerations on pathways to autoimmune injury, Gastroenterology, 120, 1485, 10.1053/gast.2001.22441 Barzilai, 2007, Epstein"Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report, Ann N Y Acad Sci, 1108, 567, 10.1196/annals.1422.059 Parker, 2010, Haemato-oncology Task Force of the British Committee for Standards in Haematology and British Transplantation Society, Br J Haematol, 149, 693, 10.1111/j.1365-2141.2010.08160.x Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Carbone, 1971, Report of the Committee on Hodgkin's disease staging classification, Cancer Res, 31, 1860 Dror, 1999, Lymphoproliferative disorders after organ transplantation in children, Transplantation, 67, 990, 10.1097/00007890-199904150-00010 Libertiny, 2001, Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients, Br J Surg, 88, 1330, 10.1046/j.0007-1323.2001.01924.x Opelz, 1993, Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients, Lancet, 342, 1514, 10.1016/S0140-6736(05)80084-4 Marino, 2010, Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience, Anticancer Res, 30, 2383 Caillard, 2013, Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score, J Clin Oncol, 31, 1302, 10.1200/JCO.2012.43.2344 Knight, 2009, Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center, J Clin Oncol, 27, 3354, 10.1200/JCO.2008.20.0857 Mumtaz, 2015, Post-transplant lymphoproliferative disorder in liver recipients: characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations, Can J Gastroenterol Hepatol, 29, 417, 10.1155/2015/517359 Man, 1993, Primary sclerosing cholangitis and Hodgkin's disease, Hepatology, 18, 1127, 10.1002/hep.1840180518 Chandok, 2012, Management of primary sclerosing cholangitis: conventions and controversies, Can J Gastroenterol, 26, 261, 10.1155/2012/426430 Cabibi, 2008, Autoimmune hepatitis following Epstein"Barr virus infection, BMJ Case Rep, 2008, 10.1136/bcr.06.2008.0071 Melosky, 1992, Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression, J Am Soc Nephrol, 2, S290, 10.1681/ASN.V212s290 Opelz, 2003, Lymphomas after solid organ transplantation: a collaborative transplant study report, Am J Transplant, 4, 222, 10.1046/j.1600-6143.2003.00325.x Robson, 2005, Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil, Am J Transplant, 5, 2954, 10.1111/j.1600-6143.2005.01125.x Moritoki, 2006, B cells and autoimmune liver diseases, Autoimmun Rev, 5, 449, 10.1016/j.autrev.2006.02.006 Lindor, 1987, Lymphocyte subsets in primary sclerosing cholangitis, Dig Dis Sci, 32, 720, 10.1007/BF01296138 Zhang, 2014, Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis, Hepatology, 60, 1708, 10.1002/hep.27313 Rigopoulou, 2012, Epstein-barr virus as a trigger of autoimmune liver diseases, Adv Virol, 2012, 987471, 10.1155/2012/987471 Vento, 1995, Epstein"Barr virus as a trigger for autoimmune hepatitis in susceptible individuals, Lancet, 346, 608, 10.1016/S0140-6736(95)91438-2 Chiba, 2004, Fatal chronic active Epstein"Barr virus infection mimicking autoimmune hepatitis, Eur J Gastroenterol Hepatol, 16, 225, 10.1097/00042737-200402000-00017 Morshed, 1992, Increased expression of Epstein"Barr virus in primary biliary cirrhosis patients, Gastroenterol Jpn, 27, 751, 10.1007/BF02806528 Pender, 2012, CD8+ T-cell deficiency, Epstein"Barr virus infection, vitamin D deficiency, and steps to autoimmunity: a unifying hypothesis, Autoimmune Dis, 2012, 189096 Smyk, 2011, Autoimmunity and environment: am I at risk?, Clin Rev Allergy Immunol, 1 Smyk, 2011, Immunopathogenesis of primary biliary cirrhosis: an old wives tale, Immun Ageing, 8, 12, 10.1186/1742-4933-8-12 Yanai, 1999, Epstein"Barr virus infection of the colon with inflammatory bowel disease, Am J Gastroenterol, 94, 1582, 10.1111/j.1572-0241.1999.01148.x Akamatsu, 2007, Epstein"Barr virus-associated lymphoma developed shortly after immunosuppressive treatment for ulcerative colitis, Clin Gastroenterol Hepatol, 5, 521, 10.1016/j.cgh.2007.02.003 Aberg, 2008, Risk of malignant neoplasms after liver transplantation: a population-based study, Liver Transpl, 14, 1428, 10.1002/lt.21475 Villeneuve, 2007, Cancer incidence among Canadian kidney transplant recipients, Am J Transplant, 7, 941, 10.1111/j.1600-6143.2007.01736.x